Tamtam Try Tamtam free
Ashland logo

Ashland account plan

Global additives specialty ingredients company

At a glance

Ashland (NYSE: ASH) is a global additives and specialty ingredients company: $1.863 billion fiscal 2026 sales, about 2,800 employees.

Ashland Inc. (NYSE: ASH) makes additives and specialty ingredients for pharmaceutical, personal care, food and beverage, architectural coatings, construction and energy customers in more than 100 countries, built mainly on cellulosics and polyvinylpyrrolidone (PVP) chemistries. It is headquartered in Wilmington, Delaware, with principal offices in Bridgewater, New Jersey, and its fiscal year ends September 30. Fiscal 2026 sales were $1.863 billion, up 2%, with Adjusted EBITDA of $385 million and net income of $4 million, after a $845 million net loss in fiscal 2025. The company had approximately 2,800 employees at the November 2026 results release, and 73% of fiscal 2025 sales were outside North America.

Business units

Strategic priorities

Execute, globalize, innovate, invest
CEO Guillermo Novo says the transformation is done and attention is now on profitable growth. Fiscal 2027 targets are about $10 million of net productivity and manufacturing optimization benefits, about $20 million of incremental Globalize sales and $45 million of innovation-driven sales.
Fix Hopewell HEC productivity
Hopewell under-absorption cost about $17.5 million versus plan in fiscal 2026, with about $5 million carrying into Q1 fiscal 2027; output is planned to rise about 25%, with a similar step the following year.
Regionalize four high-quality businesses
Globalize focuses on tablet coatings and injectables in pharma and on microbial protection and biofunctional actives in Personal Care, with local commercial, technical and supply resources; it added about $26 million of sales in fiscal 2026 against a $20 million target.
Commercialize new technology platforms
Platforms such as transformed vegetable oils, multifunctional starch, super-wetters and sugarcane bagasse cellulose address an independently validated $9 billion market, with an ambition of $200-$300 million of incremental sales in five years; 52 patents have been filed.
Financial algorithm
Growth 200-300 basis points above market, Adjusted EBITDA margin above 25% and free cash flow conversion above 50%, as set out by CFO William Whitaker at the September 2026 Innovation Day.

Latest results

In Q4 fiscal 2026 (quarter to September 30, 2026) sales rose 4% to $498 million, with volumes up 3% and pricing up 2%, while Adjusted EBITDA rose to $121 million at a 24.3% margin. For fiscal 2026, sales were $1.863 billion (organic +3% excluding Avoca) and Adjusted EBITDA $385 million versus $401 million, a 20.7% margin. Operating cash flow rose to $385 million and Ongoing Free Cash Flow to $232 million; year-end net debt was $891 million and net leverage 2.3x. Fiscal 2027 guidance is sales of $1,905-$1,975 million, Adjusted EBITDA of $405-$435 million and Ongoing Free Cash Flow conversion above 40%.

Investments and deals

Capex step-up and HEC debottlenecking
Fiscal 2027 capex is guided at up to about $140 million, versus $88 million in fiscal 2026, as HEC debottlenecking is pulled forward from 2029-2030 to be ready for a possible coatings and housing recovery.
Injectables capacity
Seven high-purity injectables launches since 2022, over $100 million of active sales opportunities and expansions in Ireland and Columbus.
Portfolio divestments
Nutraceuticals was sold in August 2024 and Avoca to Mane SA in March 2025 (proceeds $16 million); portfolio actions cut sales by approximately $208 million in fiscal 2025.
Manufacturing optimization plan
A multi-year plan targets $50 million to $55 million of pre-tax savings, and $60 million as market conditions improve, particularly in China.
Bolt-on M&A
Capital discipline leaves room for bolt-on M&A, with pharma a big area of focus, and for buying regional assets; maintenance capex runs about $50-$65 million a year.

Challenges and risks

Operational reliability
The Calvert City equipment failure cost about $15 million and weather about $5 million in fiscal 2026; the CEO said the miss was on the operating side, not in markets.
Weak energy and construction demand
Specialty Additives took a roughly $30 million net hit in energy and resources, and construction volumes were cut deliberately to prioritize higher-value applications.
Raw materials, tariffs and currency
Ashland is exposed to volatile raw material and energy costs (cotton linters, wood pulp, guar), tariffs on imports from China, the EU and India, and expects currency headwinds of $20-$25 million on fiscal 2027 sales.
Debt and legacy liabilities
Total debt was $1,384 million at fiscal 2025 year-end, and asbestos and environmental liabilities remain, with environmental reserves of $226 million.

What leadership says

“Our priorities are clear: improve operating performance, drive productivity across our network, maintain pricing discipline, build on our commercial momentum and continue to scale our globalize and innovate initiatives.”

Guillermo Novo, Chair and Chief Executive Officer · Q4 and full-year fiscal 2026 results release, November 3, 2026

“The miss was in the operating side.”

Guillermo Novo, Chair and Chief Executive Officer · Q4 fiscal 2026 earnings call, November 4, 2026

“A few years ago, we were talking about potential. Now we're talking about commercialization.”

Guillermo Novo, Chair and Chief Executive Officer · Ashland Innovation Day, September 17, 2026

“The question is not whether one project wins, it is whether the portfolio performs.”

William Whitaker, Chief Financial Officer · Ashland Innovation Day, September 17, 2026

Where a supplier can help

Plant productivity and reliability
The Hopewell productivity priority and the Calvert City outage point to demand for maintenance, process control and manufacturing performance tools across the plant network.
Capacity projects
The capex step-up to up to about $140 million for HEC debottlenecking and injectables expansions opens room for engineering, equipment and construction suppliers.
Regional go-to-market support
The Globalize priority builds local commercial, technical and supply resources for four businesses, a fit for regional distribution, logistics and sales-enablement partners.
Scaling new platforms
Commercializing new platforms relies on idle capacity and tolling partners, so contract manufacturers and regulatory or application-testing services can help speed scale-up.
Raw material and trade risk
Volatile raw materials, tariffs and currency headwinds make sourcing, procurement analytics and trade-compliance services relevant.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Ashland?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Ashland

What does Ashland do?

Ashland is a global additives and specialty ingredients company. It sells cellulosics, PVP and other ingredients to pharmaceutical, personal care, food, coatings, construction and energy customers through four segments: Life Sciences, Personal Care, Specialty Additives and Intermediates.

What is Ashland's revenue?

Fiscal 2026 sales (year to September 30, 2026) were $1.863 billion, up 2%, with Adjusted EBITDA of $385 million. Fiscal 2027 guidance is $1,905-$1,975 million of sales.

How many employees does Ashland have?

Ashland had approximately 2,800 employees at the time of its November 2026 results release, down from approximately 2,900 at September 30, 2025.

What is Ashland's strategy?

Its strategy is Execute, globalize, innovate, invest: improve plant productivity, regionalize four high-quality businesses, commercialize new technology platforms and invest with capital discipline, including bolt-on M&A.

Who leads Ashland?

Guillermo Novo is Chair and Chief Executive Officer and William Whitaker is Chief Financial Officer.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)